175 Background: It is well-known that patients with liver metastases from metastatic
castration resistant prostate cancer (mCRPC) have poorer or transient responses to many …

Purpose Little is known about the efficacy of prostate-specific membrane antigen (PSMA)–
targeted radioligand therapy (RLT) against liver metastases of metastatic castration-resistant …

e17050 Background: 177Lu-PSMA-617 was recently approved for the treatment of patients
with mCRPC in the USA. While treatment is associated with improved survival, responses to …

Background Metastatic castration-resistant prostate cancer (mCRPC) is the most
challenging stage in prostate cancer. Patient with visceral metastasis have the poorest …

2551 Introduction: Metastatic castration-resistant prostate cancer (mCRPC) poses a
therapeutic challenge with poor prognosis. The VISION trial demonstrated prolonged overall …

The aim of this study was to evaluate the efficacy of 177 Lu-PSMA-617 (Lu-PSMA) and
Selective Internal Radiation Therapy (SIRT) for the treatment of liver metastases of castration …

The aim of this study was to evaluate the efficacy of 177Lu-prostate-specific membrane
antigen (PSMA)-617 (177Lu-PSMA) and selective internal radiation therapy (SIRT) for the …

The purpose of this study was to identify previous treatments and biomarker profile features
that prognosticate overall survival (OS) in patients with mCRPC receiving 177 Lu-PSMA …

TPS5099 Background: The novel therapeutic drug 177Lu-PSMA-617 is a prostate specific
membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment …

Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …